Physician profile
Ronald Samarian
NPI 1437149234
$1,583.31
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $858 · 2020: $422 · 2021: $287 · 2022: $15.64.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $468.10 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $290.63 | 2019-2022 | |
| Allergan, INC. | $228.12 | 2019-2020 | |
| Validus Pharmaceuticals LLC | $105.65 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $104.41 | 2019-2020 | |
| Neurocrine Biosciences, INC. | $103.22 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $92.31 | 2019-2020 | |
| Abbvie INC. | $76.20 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $41.68 | 2019 | |
| Lundbeck LLC | $33.76 | 2019-2020 | |
| Bausch Health US, LLC | $22.24 | 2019 | |
| Alfasigma USA, INC. | $16.99 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronald Samarian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.